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Background-—An increased risk of acute ischemic stroke is recognized among patients with cancer. However, the mechanism
behind cancer-related stroke is unclear. In this study, we determined the presence of associated venous thromboembolism and
arterial thromboembolism and their clinical impact on patients with cancer-related stroke.
Methods and Results-—Patients with embolic stroke of undetermined source with or without cancer were evaluated for venous
thromboembolism (deep vein thrombosis [DVT] and/or pulmonary embolism) and arterial thromboembolism by using Doppler
sonography to determine the presence of lower-extremity DVT and the microembolic signal of the symptomatic cerebral
circulation, respectively. Infarct volume was determined by diffusion-weighted magnetic resonance imaging. The multivariable
linear regression and Cox proportional hazard analysis were used to investigate the effect of DVT and microembolic signal on
infarct volume and 1-year survival, respectively. Of 142 screened patients, 118 were included (37 with, 81 without cancer). Those
with cancer had a higher prevalence of DVT or microembolic signal than did the noncancer group (62.2% versus 19.8%; P<0.001).
Among patients with cancer-related stroke, DVT was associated with a greater infarct volume in magnetic resonance imaging (beta,
13.14; 95% CI, 1.62–24.66; P=0.028). Presence of DVT (hazard ratio, 16.79; 95% CI, 2.05–137.75; P=0.009) and microembolic
signal (hazard ratio, 8.16; 95% CI, 1.36–48.85; P=0.022) were independent predictors of poor 1-year survival.
Conclusions-—Patients with cancer-associated embolic stroke of undetermined source have an elevated risk of associated venous
thromboembolism and arterial thromboembolism, both of which have a significant negative impact on 1-year survival. The results
of this study may enhance our understanding of cancer-associated stroke and improve risk stratification of patients with this
disease.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/.Unique identifier: NCT02212496 ( J Am Heart Assoc. 2019;8:
e013215. DOI: 10.1161/JAHA.119.013215.)
Key Words: cancer and stroke • deep vein thrombosis • microembolic signal • thromboembolism
B oth cancer and stroke are leading causes of deathworldwide. Systemic cancer is associated with increased
risk of ischemic stroke1–3 Cryptogenic stroke can be a clue
suggesting hidden malignancy.4 Recent studies have consis-
tently reported on poor survival in patients with cancer and
stroke, especially in those with a cryptogenic subtype and
hypercoagulable states5–7
To date, several hypotheses on the mechanisms underlying
the cancer-stroke association have been suggested. Cancer
cells can produce procoagulating factors, leading to a
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thrombotic tendency.8,9 Consequent hypercoagulability is
now regarded as a hallmark of cancer-related stroke.10,11
However, the mode of clot delivery to the cerebral circulation
is still under debate. Traditionally, nonbacterial thrombotic
endocarditis was considered the cause of stroke in patients
with cancer.12 However, it is infrequently detected in clinical
settings.13 Rather, given that systemic cancer is a well-known
risk factor of venous thromboembolism, venous thrombosis
and paradoxical embolism has been suggested as a mecha-
nism for stroke.14 In addition, the microembolic signal (MES)
is relatively common in patients with cancer and cryptogenic
stroke.11 More recently, the risk of arterial thromboembolism
has increased in patients with systemic cancer.3 Taken
together, venous or arterial thromboembolism may be com-
mon in patients with cancer and play a role in the
pathophysiology of cancer-related stroke.
In this prospective study, we investigated the presence of
venous or arterial thromboembolism associated with embolic
stroke of undetermined source (ESUS) in patients with and




Consecutive patients with ESUS were prospectively recruited
between August 2014 andMarch 2018 at the SamsungMedical
Center, which is a university hospital with a comprehensive
stroke and cancer center. During the study period, patients
who: (1) had acute ischemic stroke diagnosed within 7 days
after symptom onset; (2) had embolic infarction outside the
perforator territory as revealed by diffusion-weighted imaging;
(3) lacked conventional stroke mechanisms as revealed by ECG
and intra- and extracranial vessel imaging; and (4) agreed to
participate in this study were included. After initial inclusion, we
undertook a thorough evaluation (described in the following
section) of conventional stroke mechanisms defined as evident
causesof stroke included in theCausativeClassificationSystem
(http://ccs.mgh.harvard.edu/ccs_title.php).15 If large-artery
atherosclerosis, aortogenic or cardiogenic embolism, or other
mechanisms were suspected as a cause of the index stroke,
thenwe excluded those patients. Exclusion criteria included: (1)
age <18 years; (2) single subcortical infarction; (3) inability to
perform comprehensive studies; and (4) refusal or withdrawal of
consent. This study was preregistered at Clinicaltrials.gov
(identifier: NCT02212496). The data that support the findings
of this study are available from the corresponding author upon
reasonable request.
Group Definition
The cancer group included patients with a diagnosis of or
cancer treatment during the 6 months preceding the stroke
diagnosis or the presence of recurrent or metastatic cancer.11
Those without cancer were included in the noncancer group.
In patients with cancer, data on cancer type, histology
(adenocarcinoma), and metastasis were collected. Among the
142 eligible participants, other evident etiologies were
documented by thorough investigations in 21 patients (atrial
fibrillation in 10, aortic atheroma in 2, left ventricular
thrombus in 1, left ventricular aneurysm in 1, complex
atheroma in the parent artery of <50% stenosis in 5, Takayasu
arteritis in 1, pulmonary arteriovenous malformation in 1, and
infective endocarditis in 1). Three patients withdrew their
consent because they wanted an early discharge from the
hospital before the workup was completed. Thus, a total of
118 patients with ESUS (37 in the cancer group and 81 in the
noncancer group) were included in the study.
Investigations
Workup for venous or arterial thromboembolism
All included patients were evaluated to reveal evidence of
venous or arterial thromboembolism. Venous thromboem-
bolism (VTE) was investigated primarily by Doppler sonogra-
phy for proximal (popliteal, femoral, and iliac) and distal
(peroneal, posterior and anterior tibial, and muscular veins)
lower-extremity veins and/or computed tomography pul-
monary angiography combined with venous phase computed
Clinical Perspective
What Is New?
• Venous and arterial thromboembolism are found in almost
two-thirds of embolic stroke of undetermined source
patients with cancer.
• Venous and arterial thromboembolism contribute differently
to infarct volume, although they are independently associ-
ated with poor 1-year survival.
• Hypercoagulability, rather than consumptive coagulopathy,
may be the more-contributory mechanism in cancer-related
stroke.
What Are the Clinical Implications?
• Screening for evidence of venous and arterial thromboem-
bolism in embolic stroke of undetermined source patients
with cancer may aid in the diagnosis and prognostication of
cancer-related stroke.
• Further pathophysiological studies on clot types (venous
versus arterial thromboembolism) will contribute to tailored
antithrombotic therapy for cancer-related stroke patients.
DOI: 10.1161/JAHA.119.013215 Journal of the American Heart Association 2


















 http://ahajournals.org by on D
ecem
ber 10, 2019
tomography angiography of the lower extremities. Among
patients with deep vein thrombosis (DVT), concomitant
pulmonary embolisms were sought in those who had under-
gone additional pulmonary computed tomography angiogra-
phy because of respiratory symptoms or as part of the routine
workup for DVT. Among patients with symptomatic DVT,
chronicity was defined as acute (<14 days from symptom
onset), intermediate (14–28 days from symptom onset), or
chronic (>28 days from symptom onset). Doppler ultrasound
findings of vascular wall thickening were also used to
differentiate chronic thrombi. The MES was considered a
surrogate marker for arterial thromboembolism. Patients
underwent transcranial Doppler sonography (Pioneer TC
8080; Nicolet Vascular, Madison, WI). Both of the middle
cerebral arteries were monitored by a transtemporal window
by two 2-MHz probes (insonation depth, 40–60 mm; Marc
500; Spencer Technologies, Northborough, MA) fixed with a
head frame.11 Basilar arteries were assessed using the same
apparatus rotated 90 degrees by the suboccipital window
(insonation depth, 80–100 mm).16 Doppler recordings were
performed for 30 minutes in the supine position. Patients
with ≥1 MES during the transcranial Doppler sonography
recording were classified as MES positive.11
Evaluation of the cardiogenic and arteriogenic embolic
source
Transesophageal echocardiography (TEE) was performed as a
part of the etiological investigation. The presence of a right-
to-left shunt was demonstrated by the appearance of
microbubbles in the left atrium following intravenous injection
of agitated saline that occurred spontaneously and/or after a
Valsalva maneuver.17,18 The presence of nonbacterial throm-
botic endocarditis and aortic arch atheroma was also sought.
When TEE was difficult to perform, transthoracic echocardio-
graphy was performed to exclude potential cardioembolic
sources. Regarding the right-to-left shunt and nonbacterial
thrombotic endocarditis, only the data from patients who
underwent TEE were analyzed. To detect any arrhythmia that
could act as a cardioembolic source, all participants under-
went a single routine ECG and 24-hour cardiac rhythm
monitoring or 72-hour inpatient telemonitoring. Patients with
possible large artery atherosclerosis with stenoses <50%
underwent an additional evaluation, either a carotid Doppler
ultrasound or contrast computed tomography angiography
was used to determine the vulnerability of the plaque.
Evaluation of the coagulation profile
We measured platelet count (9109/L), prothrombin time
(seconds), activated partial thromboplastin time (seconds),
fibrinogen (mg/dL), D-dimer (lg/mL), and fibrinogen degra-
dation products (lg/mL) in each patient’s blood to investigate
the presence of increased D-dimer concentration and overt
disseminated intravascular coagulopathy (DIC). A D-dimer
level of 3.00 lg/mL was used as a cut-off value to determine
elevation.19 Overt DIC was defined by The International
Society for Thrombosis and Haemostasis DIC scoring sys-
tem20: (1) platelet count (9109/L); >100=0, <100=1, or
<50=2; (2) fibrin-related markers (ie, D-dimer and fibrinogen
degradation products; lg/mL); strong increase=3, moderate
increase=2, or no increase=0; (3) prothrombin time (seconds);
<3=0, >3 but <6=2, or >6=3; and (4) fibrinogen concentration
(g/dL); <1=1 or >1=0. If the composite of these scores
summed to ≥5 points, the participant was considered to have
overt DIC.
Measurement of infarct volume
Infarct volumes were measured by diffusion-weighted imaging
and apparent diffusion coefficients calculated from the
imaging data. Magnetic resonance imaging postprocessing
was performed by the investigators (B.-y.P. and H.P.) who
were blinded to the clinical data. Using diffusion-weighted
imaging, the mean intensity value of each hemisphere was
calculated. The hemisphere with the lower value was consid-
ered as the normal hemisphere. A histogram of the intensity
values of the normal hemisphere was constructed, and voxels
with an intensity value that did not belong to 95% of the
histogram were considered as outliers and removed. The
intensity values of the remaining voxels were transformed into
z-scores. Potential infarcts were segmented by using a
threshold z-value >2. Segmented lesions were confirmed by
visual inspection and further edited as necessary. Of these
lesions, voxels with an apparent diffusion coefficient <650
were considered as infarct lesions. Clinical investigators
reviewed all segmented voxels and excluded false-positive
lesions. The infarct volume was calculated by multiplying the
number of voxels by their physical voxel dimensions.
Statistical Analysis
Based on the assumption that VTE may account for 25% of
patients from the cancer group and 5% of patients from the
noncancer group, our sample size calculation yielded 37 and
87 patients in the cancer and noncancer groups, respectively,
to reach 80% power with an alpha of 5%. Sample size was
calculated to find a significant difference in DVT prevalence
between the cancer and noncancer groups.
Statistical analyses were performed using the Statistical
Package for the Social Sciences software (ver. 24.0; IBM
Corp., Armonk, NY). The differences in demographics, pres-
ence of venous or arterial thromboembolism, plasma D-dimer
concentration, the rate of elevated D-dimer level (>3.0 lg/
mL) or overt DIC, the number of patients with nonbacterial
thrombotic endocarditis, and right-to-left shunts were com-
pared between groups using the Student t test or chi-square
test. A subgroup analysis was performed for a comparison
DOI: 10.1161/JAHA.119.013215 Journal of the American Heart Association 3
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between premorbid anticoagulant users and drug-na€ıve
patients. Univariable and multivariable linear regression
analyses were performed to evaluate factors contributing to
infarct volume adjusted for age, sex, and presence of overt
DIC. Univariable and multivariable Cox proportional hazard
analyses were performed to evaluate the potential association
between venous or arterial thromboembolism and 1-year
survival adjusted for age, sex, National Institutes of Health
Stroke Scale score, presence of overt DIC, infarct volume,
metastasis, and histology type (adenocarcinoma). The impact
of VTE and arterial thromboembolism was analyzed 3 ways:
any versus none, the presence versus absence of VTE, and the
presence versus absence of arterial thromboembolism. The
linear regression coefficient beta, 95% CIs, and 2-tailed
P values were obtained. P<0.05 was considered significant.
Standard Protocol Approvals, Registrations, and
Patient Consent
The Samsung Medical Center Institutional Review Board
approved this study. All patients and controls provided written
informed consent before participation.
Results
Study Subjects
Baseline characteristics of patients from the noncancer
(n=81) and cancer (n=37) groups are listed in Table 1.
Patients from the noncancer group were significantly younger
than those from the cancer group (P=0.003). Furthermore, the
National Institutes of Health Stroke Scale score was signif-
icantly lower (P=0.011) and hyperlipidemia was more com-
monly observed in the noncancer group (P=0.020). No other
significant differences regarding sex, comorbidities (diabetes
mellitus, hypertension, or ischemic heart disease), or the use
of tobacco and alcohol were observed between the 2 groups.
Among patients with cancer, metastasis was observed in 29
(78.4%) patients, and 22 (59.5%) patients had adenocarci-
noma.
Presence of Venous or Arterial Thromboembolism
and Comorbid Conditions
MES monitoring was conducted for a median of 2.5 days
(interquartile range, 1.00–4.25) from symptom onset, and
screening for DVT was conducted for a median of 2.6 days
(interquartile range, 1.00–4.25) from symptom onset. Com-
pared with the noncancer group, the cancer group had a
significantly higher prevalence of DVT and MES (62.2% versus
19.8%; P<0.001; Figure). Patients in the cancer group showed
a higher prevalence of both DVT and MES (18.9% versus
2.5%), DVT only (16.2% versus 6.2%), and MES only (27.0%
versus 11.1%) compared with patients in the noncancer
group, respectively. The results of the venous and arterial
thromboembolism assessment, TEE, plasma D-dimer concen-
tration measurement, and overt DIC scoring are summarized
in Table 2. Prevalence of DVT and the MES was significantly
higher in the cancer group (35.1% [95% CI, 20.2–52.5] and
45.9% [95% CI, 29.5–63.1], respectively) compared with the
noncancer group (P<0.001 for both). Patients with cancer had
higher plasma D-dimer concentrations than those without
cancer (P<0.001), showing an elevation in D-dimer concen-
tration (>3.00 lg/mL) in 24 (64.9%) patients (P<0.001). Four
(10.8%) patients from the cancer group had overt DIC, which
was not statistically different from the noncancer group
(P=0.203). Nonbacterial thrombotic endocarditis was




(n=81) Cancer (n=37) P Value
Age, y 57.715.84 66.611.28 0.003
Female sex 33 (40.7%) 14 (37.8%) 0.765
NIHSS score (IQR) 1 (0–3) 3 (0.5–6) 0.011
Cardiovascular risk factors
Hypertension 37 (45.7%) 19 (51.4%) 0.567
Diabetes mellitus 14 (17.3%) 8 (21.6%) 0.575
Hyperlipidemia 45 (55.6%) 12 (32.4%) 0.020
Ischemic heart
disease
8 (9.9%) 1 (2.7%) 0.270

















Concomitant chemotherapy 15 (40.5%)
Data are presented as meanSD or number (%), unless specified. IQR indicates
interquartile range; NIHSS, National Institutes of Health Stroke Scale.
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infrequent in our cohort of patients. In patients who
underwent TEE, no significant differences were detected in
prevalence of right-to-left shunts, or the type, amount, or
activity of the shunt (P=0.892, 0.976, 0.882, and 0.082,
respectively; Table 2).
Among patients with cancer, 4 (30.8%) had chronic DVT
based on Doppler sonography findings (vascular wall thicken-
ing). Most patients in the cancer group had proximal DVT,
whereas patients without cancer had distal DVTs (P=0.002)
more frequently. There was no difference in concomitant
pulmonary embolism or symptomaticity between the cancer
and noncancer groups (P=0.521 and P=0.051; Table 2). In the
cancer group, 5 patients were already using anticoagulants at
enrollment and 6 had started anticoagulants for the index
stroke before data collection (median,1.5 days) began. There
was no difference in demographics or patient characteristics
between anticoagulant users versus drug-na€ıve patients
(Table S1). DVT and MES were more frequently observed in
patients taking anticoagulants (P=0.028 and P=0.069, respec-
tively; Table S2), suggesting that premorbid hypercoagulability
affected the development of stroke when venous or arterial
thromboembolism was not controlled by anticoagulant use.
Impact on Infarct Volume
In patients with cancer, the overall presence of DVT and MES
was not associated with increased infarct volume (Table 3).
However, when considered separately, DVT was independently
associated with an increased infarct volume (adjusted P=0.028,
Table 3). Being female was also independently associated with
increased infarct volume (adjusted P=0.030; Table 3).
Impact on Survival
Survival analysis was performed to test the impact of venous
and arterial thromboembolism in the cancer group. Presence
Figure. Presence of DVT and MES in patients with ESUS. The
proportion of patients with DVT or MES is shown with colored
bars. The total number in the noncancer group was 81 and 37 in
the cancer group. For the noncancer group, no DVT or MES
positive=65 (80.2%), MES positive only=9 (11.1%), DVT positive
only=5 (6.2%), and DVT and MES positive=2 (2.5%). For the cancer
group, no DVT or MES positive=14 (37.8%), MES positive only=10
(27.0%), DVT positive only=6 (16.2%), and DVT and MES
positive=7 (18.9%). DVT indicates deep venous thrombosis;
MES, microembolic signal.
Table 2. Presence of DVT, MES, Right-to-Left Shunt,
Nonbacterial Thrombotic Endocarditis, Elevated Plasma
D-Dimer Concentration, and Overt DIC in Patients
Etiological Workup Noncancer (n=81) Cancer (n=37) P Value
DVT 7 (8.6%) 13 (35.1%) <0.001
Location*
Proximal 1 (14.3%) 11 (84.6%) 0.002
Distal 6 (85.7%) 7 (53.8%)
Proximal and distal 0 (0.0%) 5 (38.5%)
Concomitant PE*
Absent 7 (100.0%) 11 (84.6%)
Present 0 (0.0%) 2 (15.4%) 0.521
Symptomatic* 0 (0.0%) 6 (46.2%) 0.051
MES 11 (13.6%) 17 (45.9%) <0.001
Right-to-left shunt† 68 (86.8%) 28 (85.7%) 0.892
Amount, mb‡,†
1 to 10 20 (29.4%) 8 (28.6%) 0.882
11 to 20 19 (27.9%) 10 (35.7%)
21 to 30 19 (27.9%) 4 (14.3%)
>30 1 (1.5%) 2 (7.1%)
Type of shunt‡ 0.976
PFO (IAS) 40 (58.8%) 15 (53.6%) 0.638
Pulmonary AVF 30 (44.1%) 13 (46.4%) 0.837
PFO+AVF 11 (16.2%) 4 (14.3%) 1.000
Active shunt‡ 49 (72.1%) 15 (53.6%) 0.082
NBTE† 0 (0.0%) 1 (2.9%) 0.304
Plasma D-dimer
concentration, lg/mL
2.6 (8.31) 12.2 (13.90) <0.001
Elevated D-dimer
concentration
12 (14.8%) 24 (64.9%) <0.001
Overt DIC 3 (3.7%) 4 (10.8%) 0.203
Data are presented as number (%) or meanSD, unless specified. AVF indicates
arteriovenous fistula; DIC, disseminated intravascular coagulation; DVT, deep venous
thrombosis; IAS, interatrial shunt; mb, microbubbles; MES, microembolic signal; NBTE,
nonbacterial thrombotic endocarditis; PE, pulmonary embolism; PFO, patent foramen
ovale.
*Calculated in 7 noncancer and 13 cancer patients with DVT.
†
Only patients who completed transesophageal echocardiography were included in these
analyses (78 patients without cancer and 34 patients with cancer).
‡
Measured in 59 patients without cancer and 24 with cancer.
DOI: 10.1161/JAHA.119.013215 Journal of the American Heart Association 5
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of DVT or MES was associated with poor 1-year survival
(univariable hazard ratio=3.56, 95% CI=1.45–8.73, P=0.006;
adjusted hazard ratio=12.21, 95% CI=1.94–76.76, P=0.008;
Table 4). Presence of DVT (hazard ratio=16.79; 95% CI=2.05–
137.75; P=0.009) and MES (hazard ratio=8.16; 95% CI=1.36–
48.85; P =0.022) were independently associated with poor
1-year survival. Older age and overt DIC were also associated
with poor 1-year survival (P=0.021 and 0.017, respectively;
Table 4).
Discussion
In this study, we found that: (1) DVT or MES were observed in
two-thirds of ESUS patients with cancer; (2) DVT and MES had
different impact on infarct volume; and (3) both outcomes had
an independent impact on 1-year survival.
We found direct evidence of arterial or venous throm-
boembolism and their clinical impact on patients with cancer
and ESUS. A previous study reported that 12% of patients with
cancer who were hospitalized for stroke had experienced past
venous thromboembolism.21 Our data show a higher preva-
lence of DVT (35.1%) and MES (45.9%) among patients with
extensive malignancy (78% metastatic and 40% on chemother-
apy) and associated stroke. Although DVT may cause stroke
through paradoxical embolism, our data suggest that its high
prevalence, together with the MES, reflects a hypercoagulable
state in patients with cancer, considering that: (1) not all
patients with DVT had a right-to-left shunt; (2) there was no
difference in the prevalence and severity of right-to-left shunts
Table 3. Univariable and Multivariable Regression Analyses of Infarct Volume in Patients With Cancer
Variables
Univariable Multivariable*
Beta (95% CI) P Value Beta (95% CI) P Value
Age 0.05 (0.46 to 0.56) 0.840 0.18 (0.34 to 0.69) 0.478
Female sex 8.97 (1.43 to 19.36) 0.087 11.59 (1.25 to 21.93) 0.030
DIC 11.01 (2.52 to 24.53) 0.105 11.79 (26.50 to 2.92) 0.109
Venous or arterial thromboembolism
Any 5.55 (5.50 to 16.60) 0.307 3.11 (8.99 to 15.21) 0.595
DVT 14.93 (3.58 to 26.28) 0.013 13.14 (1.62 to 24.66) 0.028
MES 3.33 (14.43 to 7.77) 0.538 4.35 (15.45 to 6.76) 0.420
DIC indicates disseminated intravascular coagulation; DVT, deep venous thrombosis; MES, microembolic signal.
*Each multivariable regression model included age, sex, and disseminated intravascular coagulation as covariates.
Table 4. Univariable and Multivariable Cox Proportional Hazard Model for 1-Year Mortality in Patients With Cancer
Variables
Univariable Multivariable*
HR (95% CI) P Value HR (95% CI) P Value
Age 1.02 (0.99 to 1.05) 0.251 1.08 (1.01 to 1.16) 0.021
Female sex 1.63 (-3.70 to 0.72) 0.239 0.78 (4.63 to 0.13) 0.786
NIHSS score 1.01 (0.92 to 1.11) 0.897 0.95 (0.73 to 1.22) 0.665
Infarct volume, mm3 1.0001 (1.00001 to 1.0001) 0.018 1.0003 (0.99996 to 1.0001) 0.483
Overt DIC 16.47 (3.57 to 76.03) <0.001 21.75 (1.74 to 271.58) 0.017
Metastasis 1.67 (0.57 to 4.90) 0.348 1.13 (0.25 to 5.13) 0.874
Adenocarcinoma 0.364 (0.156 to 0.850) 0.020 0.23 (0.03 to 1.63) 0.140
Venous or arterial thromboembolism
Any 3.56 (1.45 to 8.73) 0.006 12.21 (1.94 to 76.76) 0.008
DVT 3.72 (1.55 to 8.96) 0.004 16.79 (2.05 to 137.75) 0.009
MES 2.51 (1.13 to 5.56) 0.023 8.16 (1.36 to 48.85) 0.022
DIC indicates disseminated intravascular coagulation; DVT, deep venous thrombosis; HR, hazard ratio; MES, microembolic signal; NIHSS, National Institutes of Health Stroke Scale.
*Each multivariate regression model included age, sex, NIHSS score, infarct volume, metastasis, histology (adenocarcinoma), and disseminated intravascular coagulation as covariates.
DOI: 10.1161/JAHA.119.013215 Journal of the American Heart Association 6
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between patients with versus without cancer; and (3) DVT was
associated with a greater infarct volume and both DVT and
MES were associated with reduced 1-year survival in patients
with cancer. Whereas previous studies indicate that the MES
was found mostly in large-artery disease or cardioem-
bolism,22,23 our data show an unexpectedly high prevalence
of the MES in patients with cancer. Thus, we considered the
MES as evidence of an increase in the formation of clots in
cancer-related stroke, presumably occurring in situ in the
arterial circulation. Previously, our group demonstrated a
higher frequency of increased plasma D-dimer concentrations
in patients with stroke and cancer, especially when conven-
tional stroke mechanisms were lacking, and suggested the
diagnostic and prognostic role of increased plasma D-dimer
concentrations in this patient population.4,5,11,24 Although
these results have been externally validated by subsequent
studies,6,10 the following question remains: Is an elevated D-
dimer level related to increased clot formation or increased
clot lysis, given that D-dimer is a by-product of fibrin
degradation? In the present study, we demonstrated an
increased prevalence of venous and arterial thromboem-
bolism, but a low prevalence of overt DIC, in patients with
ESUS and cancer, suggesting that hypercoagulability may be a
more-important mechanism than consumptive coagulopathy
in cancer-related stroke. Our recent report that cancer-cell–
derived extracellular vesicles cause coagulopathy through a
tissue factor-independent way in patients with active cancer
and ischemic stroke further supports this hypothesis.9
This study also demonstrated the impact of venous and
arterial thromboembolism on infarct volume and 1-year
survival in patients with ESUS and cancer. Based on all
currently available classification systems, stroke in patients
with cancer is classified as cryptogenic unless a conventional
stroke mechanism has been detected.15,25,26 Previous studies
have shown that cryptogenic stroke in patients with cancer is
associated with an atypical presentation and a poor 1-year
survival, and that D-dimer levels could serve as a prognostic
biomarker.5,7,27 This, taken together with our present study
results, indicates that cancer-related stroke might be a
biologically distinct entity with increased hypercoagulability as
a key feature. We suggest that active cancer should be
considered an independent etiological mechanism of stroke,
warranting a specific treatment strategy to reduce stroke
recurrence and death.1,5,28 We are currently conducting a
prospective study on the optimal anticoagulation therapy in
patients with cancer and stroke (ClinicalTrials.gov identifier:
NCT02743052).
The impact of arterial and venous thromboembolism on
infarct volume differed in our study. VTE was associated with
greater infarct volume in magnetic resonance imaging than
arterial thromboembolism. Because of slower flow rate, clots
would be of greater size in cases with VTE than in cases with
arterial thromboembolism. However, clot size may not be the
only factor to explain a greater infarct volume, unless patients
had a right-to-left shunt large enough to allow clot passage.
Moreover, 14.3% of patients with ESUS and cancer and 2
patients with DVT lacked the right-to-left shunt in this study.
Therefore, we suggest the role of DVT and the MES as
surrogate markers of increased clot formation attributable to
cancer-related hypercoagulability. Arterial and venous throm-
boembolism may have different clot formation pathophysi-
ologies, that is, different contributions from tissue factors,
circulating microparticles, mucins, and anticancer thera-
pies.29–32 Further investigation is necessary to uncover the
pathophysiology and clinical presentation according to clot
types to enable tailored antithrombotic therapy.
Our study has several strengths. First, this is the first
comprehensive study to reveal direct evidence of hypercoag-
ulability in ESUS patients with cancer. Second, imaging data
and clinical outcomes were prospectively evaluated. Third, we
have suggested a distinct mechanism of cancer-related stroke
and discussed the therapeutic implication of our results.
However, this study is not without limitations. First, it was an
observational, single-center investigation of patients of a
single ethnicity (ie, Koreans). Furthermore, our study popula-
tion was younger than other ESUS cohorts.33,34 We believe
the younger ages of patients in our cohort reflect that we
thoroughly evaluated any potential sources of embolism in all
ESUS patients. As a result, older patients were further
excluded because they had more hidden atrial fibrillation or
aortic arch pathologies. Second, the prevalence of nonbacte-
rial thrombotic endocarditis was lower in this study, compared
with previous studies. Third, the impact of different anticancer
and antithrombotic treatments on survival was not investi-
gated. Fourth, patients with cancer-related stroke were not
stratified according to their stage and type of cancer because
not all cancers share the same staging system and histolog-
ical classification. Nevertheless, most patients with stroke
and cancer had metastasis at the time of stroke diagnosis.
Fifth, survival dates were calculated by subtracting the
admission date from the death date; therefore, we measured
survival date from the first cancer-related stroke diagnosis
rather than survival date from the cancer diagnosis. Thus, the
survival date used in the study may not reflect the natural
course of each cancer, given that some patients would
develop stroke in the very last stage of disease, whereas
others may develop it earlier in the disease course. The fourth
and fifth limitations may be resolved by taking into consid-
eration the different stage and type of cancer, and the
patient’s place in the natural time course of the cancer in
subsequent studies. Sixth, the MES is best detected within
6 hours from the onset of stroke symptoms, and its
sensitivity decreases as time passes. Although our inclusion
criteria of ischemic stroke within 7 days after onset was
DOI: 10.1161/JAHA.119.013215 Journal of the American Heart Association 7
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relatively long, our MES monitoring was conducted for a
median of 2.5 days (interquartile range, 1.00–4.25) from
symptom onset. Seventh, the sample size for this study was
calculated for the comparison of DVT between 2 groups.
Therefore, the number of study participants might not have
been sufficient for the secondary outcomes, such as infarct
volume and 1-year survival, which may cause type 2 errors.
Moreover, the CIs for prevalence of DVT and the MES was
wide and probably attributable to a small sample size. Finally,
we did not measure other biomarkers, such as creatine
kinase-myocardial band, B-type natriuretic peptide, and car-
bohydrate antigen 125, in cancer-related stroke patients.35
These potential biomarkers should be incorporated in future
studies.
In conclusion, venous and arterial thromboembolism are
common in patients with ESUS and cancer. We suggest a
distinct stroke mechanism through increased clot formation in
patients with cancer. Given that venous and arterial throm-
boembolism have a significant impact on 1-year survival, early
recognition of cancer-related stroke and optimal antithrom-
botic therapy may be necessary.
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Table S1. Demographic comparison between anticoagulant users and drug-naïve 
patients among patients with cancer. 
Baseline measures 
Anticoagulant users  
(n = 11) 
Drug-naïve patients  
(n = 26) 
P value 
Age (y) 61.4 ± 9.15 68.8 ± 11.52 0.067 
Female sex 6 (54.5%) 8 (30.8%) 0.179 
    
NIHSS score (IQR) 5 (1–9) 2 (0–5) 0.189 
Cardiovascular risk factors   
Hypertension  4 (36.4%) 15 (60.0%) 0.281 
Diabetes mellitus 4 (36.4%) 4 (16.0%) 0.214 
Hyperlipidemia 3 (27.3%) 9 (36.0%) 0.715 
Ischemic heart disease 2 (18.2%) 4 (16.0%) 1.000 
Smoking history 2 (18.2%) 8 (32.0%) 0.688 

























 3 (12.0%) 















Adenocarcinoma 6 (54.5%) 16 (72.7%) 0.304 
Metastasis 9 (90.0%) 20 (76.9%) 0.645 
Concomitant chemotherapy 8 (72.7%) 14 (53.8%) 0.466 
 
Data are presented as mean ± SD or number (%), unless specified. 
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Table S2. Presence of DVT, MES, right-to-left shunt, nonbacterial thrombotic 
endocarditis, elevated plasma D-dimer concentration, and overt DIC in anticoagulant 
users vs. drug-naïve patients among cancer patients. 
Etiologic workup 
 Anticoagulant users  
(n = 11) 
Drug-naïve patients 
(n = 26) 
P value 



























Symptomatic* 4 (57.1%) 2 (33.3%) 0.592 
MES  8 (72.7%) 9 (34.6%) 0.069 




















Type of shunt‡ 1 (12.5%)  10 (50.0%) 0.054 
  PFO (IAS) 
  Pulmonary AVF 










Active shunt‡ 7 (87.5%) 8 (50.0%) 0.178 
NBTE* 1 (12.5%) 0 (0.0%) 0.286 
Plasma D-dimer 
concentration (μg/mL) 
13.9 ± 17.49 11.5 ± 12.42 0.642 
Elevated D-dimer 
concentration 
7 (63.6%) 17 (65.4%) 1.000 
Overt DIC 1 (9.1%) 3 (11.5%) 1.000 
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PE = pulmonary embolism, DVT = deep venous thrombosis, MES = microembolic signal, 
mb = microbubbles, DIC = disseminated intravascular coagulation, IAS = interatrial shunt, 
PFO = patent foramen ovale, AVF = arteriovenous fistula, NBTE = nonbacterial thrombotic 
endocarditis 
 
* Calculated in 6 drug-naïve patients and 7 anticoagulant users. 
† Only patients who completed transesophageal echocardiography were included in these 
analyses (20 drug naïve patients and 8 patients who were using anticoagulation before blood 
lab work-up) 
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